Remdesivir for COVID-19: Why Not Dose Higher?

Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02713-20. doi: 10.1128/AAC.02713-20. Print 2021 Mar 18.

Authors

Victoria C Yan¹, Florian L Muller²

Affiliations

¹ Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA victoriacyanide@gmail.com.
² Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

No abstract available

Keywords: COVID-19; GS-441524; drug metabolism; prodrug; remdesivir.

Publication types

Letter
Comment

MeSH terms

Adenosine Monophosphate / analogs & derivatives
Alanine / analogs & derivatives
Antiviral Agents* / therapeutic use
COVID-19 Drug Treatment*
Humans
SARS-CoV-2

Substances

Antiviral Agents
remdesivir
Adenosine Monophosphate
Alanine